接受干细胞移植的骨髓纤维化患者的综合临床-分子移植评分系统
本研究基于361例骨髓纤维化患者开发移植后预后评分(MTSS),训练队列205例、外部验证队列156例。多因素分析确定年龄≥57岁、Karnofsky评分<90%、血小板<150×10⁹/L、白细胞>25×10⁹/L、HLA错配无关供者、ASXL1突变及非CALR/MPL驱动突变基因为独立预测因素。4级MTSS可区分验证队列5年生存率(低危83%至极高危22%,P<.001),并预测非复发死亡(P<.001)。
要点
- MTSS基于临床、分子及移植特征,将患者分为低、中、高、极高4个风险组。
- 验证队列5年生存率:低危83%、中危64%、高危37%、极高危22%(P<.001)。
- MTSS对原发及 post-ET/PV 骨髓纤维化均适用,并预测非复发死亡(P<.001)。
核心结论
- MTSS可预测接受异基因干细胞移植的原发及 post-ET/PV 骨髓纤维化患者的移植后结局。
研究设计与样本
- 总样本361例骨髓纤维化患者,其中205例为训练队列用于建立MTSS,156例为外部验证队列。
主要发现
- 多因素分析显示年龄≥57岁、Karnofsky体能状态<90%、血小板<150×10⁹/L、移植前白细胞>25×10⁹/L、HLA错配无关供者、ASXL1突变及非CALR/MPL驱动突变基因型为独立预后预测因素。
- 最终生存模型未校正一致性指数为0.723,偏倚校正指数相似。
- 验证队列5年生存率按风险组分别为低危83%(95%CI 71%-95%)、中危64%(95%CI 53%-75%)、高危37%(95%CI 17%-57%)、极高危22%(95%CI 4%-39%),P<.001。
- 评分升高可预测非复发死亡(P<.001),在原发骨髓纤维化(0.718)及 post-ET/PV 骨髓纤维化(0.701)中均适用,且优于所有现有疾病特异性系统。
关键数值与推荐
- MTSS风险分层:低危(评分0-2)、中危(评分3-4)、高危(评分5)、极高危(评分>5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current prognostic scoring systems aim to select patients for transplantation. Here, we aimed to develop a prognostic score to determine prognosis after transplantation itself, using clinical, molecular, and transplant-specific information from a total of 361 patients with myelofibrosis. Of these, 205 patients were used as a training cohort to create a clinical-molecular myelofibrosis transplant scoring system (MTSS), which was then externally validated in a cohort of 156 patients. Multivariable analysis on survival identified age at least 57 years, Karnofsky performance status lower than 90%, platelet count lower than 150 × 109/L, leukocyte count higher than 25 × 109/L before transplantation, HLA-mismatched unrelated donor, ASXL1 mutation, and non-CALR/MPL driver mutation genotype being independent predictors of outcome. The uncorrected concordance index for the final survival model was 0.723, and bias-corrected indices were similar. Risk factors were incorporated into a 4-level MTSS: low (score, 0-2), intermediate (score, 3-4), high (score, 5), and very high (score, >5). The 5-year survival according to risk groups in the validation cohort was 83% (95% confidence interval [CI], 71%-95%), 64% (95% CI, 53%-75%), 37% (95% CI, 17%-57%), and 22% (95% CI, 4%-39%), respectively (P < .001). Increasing score was predictive of nonrelapse mortality (P < .001) and remained applicable to primary (0.718) and post-essential thrombocythemia (ET)/polycythemia vera (PV) myelofibrosis (0.701) improving prognostic ability in comparison with all currently available disease-specific systems. In conclusion, this MTSS predicts outcome of patients with primary and post-ET/PV myelofibrosis undergoing allogeneic stem cell transplantation.
引用
- Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019. PMID: 30760453. doi:10.1182/blood-2018-12-890889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。